Vik Khullar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4681975/publications.pdf

Version: 2024-02-01

44	1,629	471509 17	289244 40
papers	citations	h-index	g-index

47	47	47	1307
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy and Tolerability of Mirabegron, a Î²3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised Europeanâ€“Australian Phase 3 Trial. European Urology, 2013, 63, 283-295.	1.9	370
2	The Effects of Antimuscarinic Treatments in Overactive Bladder: A Systematic Review and Meta-Analysis. European Urology, 2005, 48, 5-26.	1.9	233
3	Fesoterodine Dose Response in Subjects With Overactive Bladder Syndrome. Urology, 2008, 71, 839-843.	1.0	96
4	Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse?. International Urogynecology Journal, 2007, 18, 1439-1443.	1.4	86
5	The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology, 2006, 68, 38-48.	1.0	85
6	The effect of mode of delivery on pelvic floor functional anatomy. International Urogynecology Journal, 2008, 19, 407-416.	1.4	80
7	The relationship between BMI and urinary incontinence subgroups: Results from EpiLUTS. Neurourology and Urodynamics, 2014, 33, 392-399.	1.5	72
8	Current controversies in urinary tract infections: ICIâ€RS 2017. Neurourology and Urodynamics, 2018, 37, S86-S92.	1.5	65
9	Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian Phase 3 trial. BMC Urology, 2013, 13, 45.	1.4	56
10	Efficacy of the Î²3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials. European Urology, 2015, 67, 11-14.	1.9	47
11	Reproducibility and reliability of pressure flow parameters in women. BJOG: an International Journal of Obstetrics and Gynaecology, 2003, 110, 774-776.	2.3	45
12	Posterior tibial nerve stimulation for overactive bladderâ€”techniques and efficacy. International Urogynecology Journal, 2020, 31, 865-870.	1.4	41
13	Pressure flow study: A useful diagnostic test of female lower urinary tract symptoms. Neurourology and Urodynamics, 2004, 23, 104-108.	1.5	29
14	The use of laser in urogynaecology. International Urogynecology Journal, 2019, 30, 683-692.	1.4	27
15	?Unblinding? in randomized controlled drug trials for urinary incontinence: Implications for assessing outcomes when adverse effects are evident. Neurourology and Urodynamics, 2005, 24, 13-20.	1.5	24
16	Patientâ€reported outcomes with the Î² 3 â€adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourology and Urodynamics, 2016, 35, 987-994.	1.5	23
17	Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms. European Urology, 2019, 75, 129-168.	1.9	19
18	Intraobserver and interobserver reliability of the three-dimensional ultrasound imaging of female urethral sphincter using a translabial technique. International Urogynecology Journal, 2012, 23, 1063-1068.	1.4	18

#	Article	IF	Citations
19	Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?. International Urogynecology Journal, 2012, 23, 179-192.	1.4	17
20	Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study. Neurourology and Urodynamics, 2016, 35, 819-825.	1.5	16
21	Racial differences in female urethral morphology and levator hiatal dimensions: An ultrasound study. Neurourology and Urodynamics, 2012, 31, 502-507.	1.5	15
22	Interstitial cystitis/bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome. Post Reproductive Health, 2020, 26, 87-90.	0.9	13
23	Clinical value of a patientâ€reported goalâ€attainment measure: the global development of selfâ€assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms. Neurourology and Urodynamics, 2014, 33, 90-94.	1.5	12
24	Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourology and Urodynamics, 2015, 34, 438-443.	1.5	12
25	Midurethral slings for treatment of stress urinary incontinence review. Neurourology and Urodynamics, 2019, 38, S70-S75.	1.5	12
26	Abnormal vaginal microbiome associated with vaginal mesh complications. Neurourology and Urodynamics, 2019, 38, 2255-2263.	1.5	11
27	The role of bladder instillation in the treatment of bladder pain syndrome: Is intravesical treatment an effective option for patients with bladder pain as well as LUTS?. International Urogynecology Journal, 2020, 31, 1387-1392.	1.4	11
28	Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. BJU International, 2013, 112, 820-829.	2.5	10
29	Personal goals and expectations of OAB patients in the UK. Neurourology and Urodynamics, 2017, 36, 1194-1200.	1.5	9
30	European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder. International Urogynecology Journal, 2013, 24, 1529-1536.	1.4	8
31	Urodynamics are necessary for patients with asymptomatic pelvic organ prolapse. Neurourology and Urodynamics, 2018, 37, 2841-2846.	1.5	8
32	How can we improve the diagnosis and management of bladder pain syndrome? Part 2:ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S71-S81.	1.5	8
33	Tolterodine ER reduced increased bladder wall thickness in women with overactive bladder. A randomized, placeboâ€controlled, doubleâ€blind, parallel group study. Neurourology and Urodynamics, 2018, 37, 237-243.	1.5	7
34	Recommendations and future research initiative to optimize bladder management in pregnancy and childbirth International Consultation on Incontinence â€•Research society 2018. Neurourology and Urodynamics, 2019, 38, S104-S110.	1.5	7
35	Time-to-effect with darifenacin in overactive bladder: a pooled analysis. International Urogynecology Journal, 2011, 22, 1573-1580.	1.4	6
36	Validation study of ultrasound bladder wall thickness measurements. International Urogynecology Journal, 2019, 30, 1575-1580.	1.4	6

#	Article	IF	Citations
37	Under what circumstances should stress incontinence surgery be performed at the same time as prolapse surgery? ICIâ€RS 2015. Neurourology and Urodynamics, 2017, 36, 909-914.	1.5	5
38	Emerging drugs for overactive bladder. Expert Opinion on Emerging Drugs, 2015, 20, 613-624.	2.4	4
39	How can we improve the diagnosis and management of bladder pain syndrome? Part 1: ICIâ€RS 2018. Neurourology and Urodynamics, 2019, 38, S66-S70.	1.5	4
40	Does size matter? Perineometer and digital examination of a model levator hiatus. Neurourology and Urodynamics, 2020, 39, 1338-1344.	1.5	3
41	Does cystoscopy method affect the investigation of bladder pain syndrome/interstitial cystitis?. International Urogynecology Journal, 2021, 32, 1229-1235.	1.4	3
42	Female pelvic surgical devices and techniques need better evidenceâ€based medicine. Neurourology and Urodynamics, 2010, 29, 670-675.	1.5	2
43	Can we harness the placebo effect to improve care in lower urinary tract dysfunction? ICIâ€RS 2019. Neurourology and Urodynamics, 2020, 39, S80-S87.	1.5	2
44	Urogynaecology and Ehlersâ€“Danlos syndrome. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 579-585.	1.6	2